1. Zaire ebolavirus-glycoprotein-specific antibody responses were detected in all participants receiving vaccination doses from 300,000 to 50 million plaque-forming units (PFU). 2. Fever was reported in 13-30% of participants receiving the recombinant vesicular stomatitis virus-vectored Zaire ebolavirus (rVSV-ZEBOV) vaccination. Evidence Rating Level: 2 (Good) Study Rundown: In August 2014, the WHO declared the Ebola outbreak
↧